My profession and expertise in oncology care affords me a very special and unique opportunity to help alleviate a patient’s stress and uncertainty at a most challenging and vulnerable time in their life. By combining exceptional patient care with the most cutting edge treatments, I am able to tailor each patient’s plan of care specifically to meet their individual needs and concerns.
Medical Oncology and Internal Medicine
National Cancer Institute, Medical Oncology
Georgetown University Medical Center
Louisiana State University Medical Center
Dr. Neelima Denduluri earned her medical degree from the Louisiana State University Medical Center, where she served as President of the American Medical Student Association. Upon graduation she received the “Exemplar of Desirable Attitudes of the Physician Towards His Patients” award, which is bestowed upon one graduating senior. She completed her Internal Medicine residency at Georgetown University Medical Center. During her fellowship at the National Cancer Institute, she was honored with the distinction of serving as Chief Fellow. She later served as Assistant Clinical Investigator and Staff Physician at NCI before joining Virginia Cancer Specialists.
Dr. Denduluri remains highly involved in the local community by participating in community outreach, speaking to support groups, and volunteering at the Arlington Free Clinic since 1999. She has consistently been named as a Top Doctor in Northern Virginia Magazine and Washingtonian magazine, and she has been featured in both local and national media for her expertise in breast cancer.
In addition to her passion for patient care, Dr. Denduluri’s dedication to the advancement of medicine has led her to take on multiple leadership roles, including: Associate Chair of the US Oncology Breast Cancer Research Committee; Former Chair of the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Committee; and Cancer Committee Chairman at Virginia Hospital Center. Dr. Denduluri also currently serves as an associate and principal investigator on many clinical trials, and is a steering committee member for NAPBC accreditation for the Reinsch Pierce Family Center for Breast Health.
Dr. Denduluri continues to be active in medical education, currently serving as Clinical Assistant Professor at Georgetown University Medical Center. She has also taught attending students and residents of Virginia Commonwealth University, as well as oncology fellows at the National Navel Medical Center in Bethesda, MD. Dr. Denduluri has published multiple articles and abstracts, and her work has been presented at various national meetings, including the American Society of Clinical Oncology and the San Antonio Breast Cancer Symposium.
Dr. Denduluri is fluent in English, Spanish, and Telugu (an Indian language).
Medical Oncologist and Leader Named Advocacy Champion by the American Society of Clinical OncologyRead More
Neelima Denduluri, MD of Virginia Cancer Specialists contributes to ASCO Guideline for Early Breast Cancer TreatmentRead More
Pretreatment Psychoneurological Symptoms and Their Association With Longitudinal Cognitive Function and Quality of Life in Older Breast Cancer Survivors.Read More
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.Read More
Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study.Read More
Using a Neoadjuvant Approach for Evaluating Novel Therapies for Patients With Breast Cancer.Read More
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.Read More
Patient Case Lessons: Endocrine Management of Advanced Breast Cancer.Read More
Lifestyle Interventions to Improve Cardiorespiratory Fitness and Reduce Breast Cancer Recurrence.Read More
Patient Case Lessons: Endocrine Management of Advanced Breast CancerRead More
American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority PopulationsRead More
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.Read More
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.Read More
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.Read More
Innovations in American Society of Clinical Oncology Practice Guideline Development.Read More
Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary.Read More
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.Read More
Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology PracticesRead More
Coginitive Impairments in Older Breast Cancer Patients Prior to Systemic Therapy: Is There an Interaction between Cancer and ComorbidityRead More
Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?Read More
Bridging to Survivorship in Breast Cancer-How BMI Weighs In?Read More
Bridging to survivorship in breast cancer: learning how treatment impacts mental health among early stage breast cancer survivors.Read More
Risk of acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy for early breast cancer in the community setting.Read More
Phase II study of the multikinase inhibitor dovitinib (TKI258) or placebo in combination with fulvestrant in postmenopausal, endocrine resistant HER2-/HR+ breast cancerRead More
Concordance between the 21-gene recurrence score (RS) and the 70-gene profile (MP) in breast cancer (BC) patients (pts)Read More
Ixabepilone: Clinical Role in Metastatic Breast CancerRead More